Bristol-Myers Squibb Co.
Stock Exchange: XNYS • Ticker: BMY • HQ: New York, NY, US • Employees: approx. 25,000
Ranking by technical area
Ranking by strategic pillar
Bristol-Myers Squibb remains 13th. Although it is a leader in Patents & Licensing and has improved moderately in other areas, this is outweighed by significant falls in Market Influence & Compliance and in R&D. The company was found to have engaged in corrupt practice in China. In R&D, it has a small pipeline of relevant products and a conservative approach to sharing clinical trial data. Bristol-Myers Squibb does have an access-to-medicine strategy, but it is not clearly aligned with corporate strategy. The company consistently engages in licensing, now also for hepatitis C products. It has equitable pricing strategies for the same number of products as in 2014. Despite a strong approach to philanthropy, it lags in capacity building, particularly in the areas of pharmacovigilance and supply chain strengthening.
Change since 2014
Has a better-defined access-to-medicine strategy than in 2014.
Maintains low transparency about its stakeholder engagement and marketing activities.
Has breached civil law relating to corruption in China.
Has a significantly smaller pipeline of products for people in low- and middle-income countries (LMICs), less than half the size.
Improves its accountability for its sales agents’ pricing practices by monitoring prices.
Has equitable pricing strategies for the same number of products as in 2014.
Has agreed pro-access licensing terms for daclatasvir (Daklinza®) for hepatitis C.
Is less active in building pharmacovigilance capacity than in 2014.
Contributes to a new donation programme aimed at treating patients co-infected with HIV and chronic hepatitis C virus (HCV).
Expand access approaches beyond HIV/AIDS and hepatitis C. Bristol-Myers Squibb can consider expanding its access-oriented product deployment approach (e.g., its equitable pricing strategy for atazanavir (Reyataz®)) beyond products for HIV/AIDS and hepatitis C. It can explore similar approaches for its ischaemic heart disease and stroke products.
Link R&D strategy to need in low- and middle-income countries. Bristol-Myers Squibb can clearly link its R&D strategy to high-burden diseases and access needs in low- and middle-income countries. The company can also develop plans to ensure new products are accessible in these markets soon after they leave the pipeline.
Expand packaging adaptations to support rational use. Bristol-Myers Squibb can expand the range of factors (beyond environmental adaptations) that it takes into account when adapting the brochures and packaging of its products. For example, it can systematically take account of local languages, literacy levels, cultural factors and demographic considerations for children and elderly populations.
Expand strategic capacity building activities to support local access to medicine. Bristol-Myers Squibb has a strong approach to philanthropic capacity building in health-related areas, beyond the production and supply of medicines. It can use its experience here to broaden and strengthen its capacity building activities within the pharmaceutical value chain: e.g., to strengthen supply chain management and pharmacovigilance systems.
Sales and operations
Bristol-Myers Squibb produces biopharmaceuticals for oncology, immuno-oncology, immunoscience, cardiovascular, fibrotic diseases, and genetically defined diseases. In July 2016, the company announced the acquisition of Cormorant Pharmaceuticals, a company focused on the development of therapies for cancer and rare diseases, for USD 520 mn. Bristol-Myers Squibb has sales in 37 countries within the scope of the Index. Revenues outside of the US and Europe account for approximately one third of total sales.
Sales in countries in scope
Sales by division
Sales by region
Portfolio and pipeline
Bristol-Myers Squibb has a small portfolio of 16 relevant products, and a small pipeline of five R&D projects that address the needs of people in countries in scope.
The majority of Bristol-Myers Squibb’s portfolio is divided between communicable and non-communicable diseases, with nine and seven medicines respectively. In communicable diseases, the company is mainly active in HIV/AIDS and viral hepatitis. In 2015, Bristol-Meyers Squibb gained market approval from the FDA for daclatasvir (Daklinza®) for the treatment of chronic HCV hepatitis C virus genotype 3.
Products per disease category
Its portfolio targets communicable and non-communicable diseases, namely liver, cardiovascular diseases and mental health conditions.
The company’s R&D projects for high-burden diseases are all in early stages of development: it has medicines in phase I testing for HIV/AIDS, diarrhoeal diseases and ischaemic heart disease, and a discovery-stage project for dengue.
This latter project for dengue is its only project that clearly targets a high-priority product gap with low commercial incentive. None of its relevant projects have been shown to have moved to a new stage of development since 2014.
None of Bristol-Myers Squibb’s relevant pipeline projects are being conducted through R&D partnerships with third-parties.
First-line treatments and essential medicines
Of the 16 medicines in Bristol-Myers Squibb’s portfolio, 12 are listed on the WHO EML and/or are first-line treatments: e.g., daclatasvir (Daklinza®), entecavir (Baraclude®), and efavirenz (Sustiva®).
Pipeline by stage of development
– Innovative medicines and vaccines
Bristol-Myers Squibb’s pipeline for high-burden diseases focuses entirely on innovative medicines, including a PD-L1 inhibitor for HIV/AIDS, a TYK2 inhibitor for diarrhoeal diseases and two medicines for ischaemic heart disease.
Pipeline by stage of development
– Adaptive medicines and vaccines
Bristol-Myers Squibb supports paediatric R&D via its investigator-sponsored research programme. It is adapting products for diseases in scope, but did not provide evidence of how they meet needs of people in LMICs.